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Keywords

Management of intracoronary thrombus in patients presenting more than
12 hours after the onset of ST elevation myocardial infarction is challenging.
We present such a case which had massive thrombus in left anterior descending
artery. It was managed successfully with dual antiplatelet agents and factor Xa
inhibitor rivaroxaban administered orally.
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Introduction
Cardiovascular disease burden is rising in Africa [1]. Early
reperfusion is the modality of choice for treating STEMI
(ST elevation myocardial infarction) [2]. Primary PCI
(percutaneous coronary intervention) is the preferred
method of reperfusion when it can be performed in a
timely fashion by experienced operators [3]. There is a
significant thrombus burden in nearly 30% of patient presenting with STEMI [4]. Management of thrombus during PCI for acute myocardial infarction could include
aspiration thrombectomy, however, routine rheolytic
thrombectomy has not shown clinical benefit [3]. We
present here the case of a young African male presenting
late with a large anterior and inferior wall myocardial
infarction. He was found to have massive – extensive
grade IV intracoronary thrombi [5] that was managed
with dual antiplatelet agents and rivaroxaban.

Case report
We present the case of a 39-year-old African male who presented to Lutheran Medical Center in Arusha, Tanzania
more than 12 hours after the onset of chest pain with ante-

rior and inferior wall STEMI. He had no known risk factors for coronary artery disease, no history of drug abuse,
or medical illness in the past. Since there was no cardiac
catheterization facility available in the area, he was managed medically without fibrinolysis with aspirin, enoxaparin, and atenolol, and discharged home in 2 days. Two
days after discharge he came to The Aga Khan Hospital in
Dar es Salaam, Tanzania for coronary angiogram with possible PCI. On arrival, the patient had no chest pain. The
ECG showed evolved anteroseptal and inferior wall
myocardial infarction with persistent ST elevation in the
anterior leads. (Fig. 1A). Because of the ECG evidence of
anterior as well as inferior myocardial infarction it was felt
that the patient probably had a large wrap around LAD
(left anterior descending artery) which caused his index
event. He received aspirin 300 mg, clopidogrel 600 mg,
and atorvastatin 80 mg orally, and coronary angiography
was performed the next day. The procedure was carried
out by the right femoral approach, using six French sheath,
six French Judkins coronary catheters, and six French pigtail catheter for left ventriculogram. At the end of the procedure, hemostasis was obtained by local pressure.
The coronary angiogram revealed a nondominant right
coronary artery without stenosis. There was no right to
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Figure 1. (A) ECG prior to the first coronary angiogram. (B) ECG prior to the follow-up coronary angiogram.

left collaterals. The LCA (left coronary artery) showed a
large caliber left main trunk without stenosis. The LAD
was of large caliber with a filling defect near the ostium
which appeared to be a retrograde propagation from the
proximal thrombus present at the site of probable ruptured plaque (Fig. 2A). The mid to distal LAD had a long
linear filling defect compatible with thrombus. Distal
LAD wrapped around the apex and continued as the
PDA (posterior descending artery), which also appeared
to have diffuse intraluminal thrombus (Fig. 2B). There
was TIMI three flow in the LAD. The ramus intermedius
was of moderate caliber reaching up to the apex without
stenosis. The LCF (left circumflex) consisted essentially of
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a large posterolateral branch without stenosis. Left ventriculogram showed akinesia of left ventricular apex and
adjoining distal anterolateral, and inferior walls with
estimated ejection fraction (LVEF) of 30–35%. LVEDP
(Left ventricular end diastolic pressure) was 22 mmHg.
Because of the massive thrombus burden in the LAD
extending up to the ostium it was felt that the catheter aspiration extraction may not completely remove the thrombus
and would carry a risk of embolization into the ramus and
LCF. Moreover, the infarct appeared to be completed.
Hence, it was decided to manage the patient conservatively
and at a later date when the thrombus had cleared, PCI for
any residual significant stenosis could be considered.
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Figure 2. (A) RAO caudal view of LCA (left coronary artery) showing LAD (left anterior descending artery) ostial thrombus (white arrow),
proximal thrombus, and ruptured plaque (black arrow). (B) RAO cranial view of LCA showing distal and apical LAD with linear thrombus (white
arrows). The LAD wraps around the apex and continues into PDA (posterior descending artery) which also has thrombi (black arrows). (C) RAO
caudal view of LCA during the follow-up angiogram showing complete resolution of LAD thrombi. (D) RAO cranial view of LCA during the
follow-up angiogram showing complete resolution of LAD and PDA thrombi.

On the same day of the coronary angiogram, a 2-D
echocardiogram showed normal LV chamber size with
dyskinetic apex, akinetic anterior wall, and anterior interventricular septum. Estimated LVEF was about 35% with
possible apical intramural thrombus.
The patient was placed on daily oral dose of aspirin
75 mg, clopidogrel 75 mg, spironolactone 12.5 mg, and
atorvastatin 80 mg as well as carvedilol 3.125 mg twice a
day. For anticoagulation, rivaroxaban 20 mg a day was
chosen because anticoagulation with warfarin is problematic given the general difficulty and reliable monitoring of
INR, as well as patient compliance with any complex
warfarin dosing regimen. [6]
5 weeks later, the patient returned for a repeat coronary angiogram. He had complaint of mild chest discomfort when walking fast but no symptoms of heart failure.
ECG showed further evolution of anteroseptal and inferior wall myocardial infarctions with less ST elevation and
more T-wave inversions in precordial leads (Fig. 1B).
Repeat coronary angiogram was carried out via right
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femoral approach using six French sheath and catheters.
LVEDP was 12 mmHg. Coronary angiogram showed no
change in RCA, ramus, and LCF. LAD was of large caliber
going around the apex into a PDA. The ostium was
widely patent without filling defect. The proximal LAD
was also of larger caliber without filling defect or stenosis
with mild plaque and some swirling of contrast (Fig. 2C).
The mid, distal LAD and the PDA were patent without
stenosis or filling defect (Fig. 2D). Echocardiogram
showed hypokinesia of apical septum, apical lateral wall,
and mid-interventricular septum with estimated LVEF
about 40%. There was no evident intramural thrombus at
the LV apex. The patient was discharged home on same
medications except to stop rivaroxaban when the remaining 1 week supply of the medication was finished.

Discussion
ST elevation myocardial infarction is generally caused by
a coronary artery plaque rupture, platelet aggregation at
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the site of rupture followed by clot formation resulting in
occlusion of a culprit coronary vessel. Primary PCI
performed promptly in an experienced center is currently
the preferred method of reperfusion of the occluded
artery [3]. Management of thrombus during PCI for acute
myocardial infarction could include aspiration thrombectomy, however, routine rheolytic thrombectomy has not
shown clinical benefit [3].
During the performance of the PCI, occasionally the
culprit vessel is found to have massive thrombus burden.
The optimal management of massive thrombus burden is
not known and the treatment is usually individualized. If
the thrombus burden is very large as in the case of a
saphenous vein graft occlusion, there is higher rate of
acute failure (8.2%) [7]. For saphenous vein grafts, fibrinolytic therapy is no longer used for thrombus-containing lesions, but rheolytic or manual aspiration
thrombectomy is sometimes employed [8]. When extensive thrombi are seen in aneurysmal coronary arteries,
they have been variously managed. They have been treated with intracoronary thrombolysis followed by heparin
and warfarin [9], aspiration thrombectomy followed by
prolonged intravenous infusion of a glycoprotein IIb/IIIa
inhibitor [10], guide catheter aspiration together with
the use of distal protection devices, withdrawal of a distal filter vascular protection device together with adjunct
glycoprotein IIb/IIIa inhibitor [11]. Recently in patients
with large acute anterior wall STEMI, aspiration
thrombectomy was not found to significantly reduce
infarct size [12].
In our case, the patient had the coronary angiogram
5 days after the acute event. The risk of thrombectomy of
massive thrombus burden outweighed potential benefit
especially since the LAD had TIMI grade 3 flow despite
the clots. Although there was a potential danger of recurrent occlusion from thrombus propagation, it was felt
that medical management would be more prudent. Since
the thrombus genesis has both platelet and the coagulation factor components, a triple anticoagulant therapy
was chosen. In this part of the world, the use of warfarin
and adjusting its dose to a therapeutic INR range is particularly challenging because of inconsistencies in laboratory results and lack of reliability of patient compliance.
Hence, in addition to the guidelines recommended therapy of acute myocardial infarction including dual antiplatelet agents of ASA and clopidogrel, we chose to use
rivaroxaban after confirming normal renal function.
Rivaroxaban is approved for use in nonvalvular atrial
fibrillation for the prevention of stroke and systemic
embolism, treatment of pulmonary embolism, as well as
treatment and prevention of DVT (deep vein thrombosis). In patients with a recent acute coronary syndrome,
low-dose rivaroxaban was found to reduce the risk of the
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composite end point of death from cardiovascular causes,
myocardial infarction, or stroke [13]. Because of the
massive thrombus, we arbitrarily used the recurrent
pulmonary embolism and DVT prophylaxis dose of this
newer oral anticoagulant.
Rivaroxaban, because of its potent factor Xa inhibition
reduces clotting. Besides its anticlotting activity, in experimental study it was shown to modify fibrin network with
thicker fibers and larger pores, which resulted in greater
permeation of flow through the clots [14]. Hence, it may
facilitate resolution of thrombi.
In our case, the medical regimen used resulted in the
resolution of the massive intracoronary thrombus. Incidentally, there was also resolution of left ventricular apical
intramural thrombus which has been reported previously
with the use of rivaroxaban [15]. Although it cannot be
proven, it is plausible that rivaroxaban may have contributed to the resolution of the coronary thrombus
through the naturally occurring intrinsic thrombolysis.
More data need to be generated to confirm this.

Conclusion
Management of massive intracoronary thrombus burden is
challenging despite the availability of various interventional
and pharmacologic tools. In our case, a conservative
approach of triple therapy with aspirin, clopidogrel, and
rivaroxaban produced the desired outcome of resolution of
extensive thrombus in the LAD without reocclusion. More
studies are needed to address this problematic issue.
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